Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:CLRB OTCMKTS:CTYX NASDAQ:MTVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$3.39-4.8%$3.20$2.00▼$5.00$16.58M2.2588,440 shs43,533 shsCLRBCellectar Biosciences$5.15+1.4%$4.86$4.11▼$67.50$16.22M0.52113,313 shs43,362 shsCTYXCurative Biotechnology$0.01-7.5%$0.01$0.00▼$0.22$3.85M-33.993.01 million shs102,100 shsMTVAMetaVia$1.50+115.5%$0.67$0.56▼$3.75$16.84M0.2541,993 shs89.67 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-4.78%-6.09%-2.02%+27.20%+27.97%CLRBCellectar Biosciences+1.38%+2.39%+18.66%-51.15%-91.94%CTYXCurative Biotechnology0.00%+17.30%-2.94%+25.32%-25.56%MTVAMetaVia+115.55%+117.39%+134.38%+116.76%+149,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$3.39-4.8%$3.20$2.00▼$5.00$16.58M2.2588,440 shs43,533 shsCLRBCellectar Biosciences$5.15+1.4%$4.86$4.11▼$67.50$16.22M0.52113,313 shs43,362 shsCTYXCurative Biotechnology$0.01-7.5%$0.01$0.00▼$0.22$3.85M-33.993.01 million shs102,100 shsMTVAMetaVia$1.50+115.5%$0.67$0.56▼$3.75$16.84M0.2541,993 shs89.67 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos-4.78%-6.09%-2.02%+27.20%+27.97%CLRBCellectar Biosciences+1.38%+2.39%+18.66%-51.15%-91.94%CTYXCurative Biotechnology0.00%+17.30%-2.94%+25.32%-25.56%MTVAMetaVia+115.55%+117.39%+134.38%+116.76%+149,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/ACLRBCellectar Biosciences 2.50Moderate Buy$375.007,181.55% UpsideCTYXCurative Biotechnology 0.00N/AN/AN/AMTVAMetaVia 3.00Buy$7.50400.00% UpsideCurrent Analyst Ratings BreakdownLatest CTYX, MTVA, AIMD, and CLRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.008/14/2025CLRBCellectar BiosciencesRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$110.87K142.42N/AN/A$5.51 per share0.62CLRBCellectar BiosciencesN/AN/AN/AN/A$8.98 per shareN/ACTYXCurative BiotechnologyN/AN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$4.99N/A∞N/AN/A-108.25%-56.94%11/5/2025 (Estimated)CLRBCellectar Biosciences-$44.58M-$19.91N/AN/AN/AN/A-486.67%-150.57%11/17/2025 (Estimated)CTYXCurative BiotechnologyN/AN/A0.00∞N/AN/AN/AN/AN/AMTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-212.00%-107.21%11/6/2025 (Estimated)Latest CTYX, MTVA, AIMD, and CLRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CLRBCellectar Biosciences-$3.60-$3.39+$0.21-$3.39N/AN/A8/13/2025Q2 2025AIMDAinosN/A-$0.99N/A-$0.99N/AN/A8/7/2025Q2 2025MTVAMetaVia-$0.32-$0.26+$0.06-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/ACLRBCellectar BiosciencesN/AN/AN/AN/AN/ACTYXCurative BiotechnologyN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.962.882.61CLRBCellectar BiosciencesN/A2.152.15CTYXCurative BiotechnologyN/AN/AN/AMTVAMetaViaN/A2.082.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/ACLRBCellectar Biosciences16.41%CTYXCurative BiotechnologyN/AMTVAMetaVia1.37%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%CLRBCellectar Biosciences5.04%CTYXCurative BiotechnologyN/AMTVAMetaVia0.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.66 million4.17 millionNot OptionableCLRBCellectar Biosciences103.19 million3.03 millionOptionableCTYXCurative Biotechnology4388.50 millionN/ANot OptionableMTVAMetaVia824.20 million24.00 millionN/ACTYX, MTVA, AIMD, and CLRB HeadlinesRecent News About These CompaniesQ3 Earnings Forecast for MetaVia Issued By HC WainwrightSeptember 9, 2025 | americanbankingnews.comQ1 Earnings Estimate for MetaVia Issued By HC WainwrightSeptember 7, 2025 | americanbankingnews.comMetaVia assumed with a Buy at H.C. WainwrightSeptember 4, 2025 | msn.comMetaVia to Present at Upcoming Investor and Industry ConferencesAugust 26, 2025 | prnewswire.comMTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025…August 13, 2025 | finance.yahoo.comMetaVia Inc. Reports Q2 2025 Financial Results and Strategic ProgressAugust 12, 2025 | msn.comMetaVia Reports Second Quarter 2025 Financial Results and Provides ...August 9, 2025 | morningstar.comMMetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | prnewswire.comMetaVia Extends Phase 1 Trial for Obesity DrugAugust 6, 2025 | tipranks.comMetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First PatientAugust 6, 2025 | prnewswire.comMetaVia seeks Syntekabio help to explore additional DA-1241 indicationsAugust 6, 2025 | thepharmaletter.comTMetaVia Partners with Syntekabio for DA-1241 ResearchAugust 4, 2025 | tipranks.comMetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241August 4, 2025 | prnewswire.comMetaVia Inc.: MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum ...July 10, 2025 | finanznachrichten.deMetaVia doses first patient in 48 mg MAD cohort of its Phase 1 trialJuly 10, 2025 | msn.comMetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated DoseJuly 9, 2025 | prnewswire.comOTC Markets Hosts Virtual Investor Presentation with HH Kim, President and CEO of MetaVia Inc., and David Bautz, PhD, Senior Analyst at Zacks SCRJune 27, 2025 | msn.comMTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…June 24, 2025 | finance.yahoo.comMetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific SessionJune 21, 2025 | prnewswire.comMetaVia to Present at the Life Sciences Virtual Investor Forum June 12thJune 10, 2025 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTYX, MTVA, AIMD, and CLRB Company DescriptionsAinos NASDAQ:AIMD$3.39 -0.17 (-4.78%) As of 09/15/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Cellectar Biosciences NASDAQ:CLRB$5.15 +0.07 (+1.38%) Closing price 09/15/2025 04:00 PM EasternExtended Trading$5.16 +0.01 (+0.29%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Curative Biotechnology OTCMKTS:CTYX$0.0099 0.00 (-7.48%) As of 09/12/2025Curative Biotechnology, Inc. engages in the provision of software solutions for the healthcare market. Its products include MedFlash, electronic Personal Health Manager, Medical Alert, personal emergency response services, product and medical transcription, disease management, revenue cycle management, and medical consulting-billing. The company was founded by Jon Pevzner on July 29, 1995 and is headquartered in Boca Raton, FL.MetaVia NASDAQ:MTVA$1.50 +0.80 (+115.55%) As of 09/15/2025 04:00 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
